Skip to main content
Top
Published in: International Urology and Nephrology 4/2014

01-04-2014 | Urology - Original Paper

Actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia: temporal trends of prescription and hospitalization rates over 5 years in a large population of Italian men

Authors: Luca Cindolo, Luisella Pirozzi, Caterina Fanizza, Marilena Romero, Petros Sountoulides, Claus G. Roehrborn, Vincenzo Mirone, Luigi Schips

Published in: International Urology and Nephrology | Issue 4/2014

Login to get access

Abstract

Purpose

The purpose of the study is to estimate the trends in drug prescriptions and the hospitalization rates for lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH) in real-life clinical practice, using information deriving from administrative databases of the Italian health care system.

Methods

Prescription data on approximately 1,500,000 men over 40 were examined, and prescribed boxes of alpha-blockers (ABs) and/or 5 alpha reductase inhibitors (5ARI) were calculated for 5 consecutive years, from 2004 to 2008. Annual use prevalence and incidence rates for each drug class and for the combination therapy (CT) were calculated according to age for the entire study period. Hospitalization rates for reasons related to LUTS/BPH were also evaluated for the same time period.

Results

The overall distribution of drugs for LUTS/BPH, in terms of number of boxes prescribed, increased by 43 %. This increase was accounted for by both classes of drugs although it was greater for 5ARI than for AB (+49 vs +41 %). The prevalence of CT showed a substantial increase to almost 25 % in patients aged ≥75. Hospitalization rate for BPH/LUTS-related reasons decreased during the study period (8 and 3 % per year for non-surgical and surgical reasons, respectively).

Conclusions

The prevalence of the use of drugs prescribed for LUTS/BPH has steadily increased. An increase in terms of prescribed boxes was observed for both classes of drugs, even though the increase was greater for 5ARIs. The reduction in the hospitalization rates needs additional researches.
Literature
1.
go back to reference Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, N’dow J, Nordling J, de la Rosette JJ (2013) EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 64(1):118–140PubMedCrossRef Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, N’dow J, Nordling J, de la Rosette JJ (2013) EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 64(1):118–140PubMedCrossRef
2.
go back to reference Anderson JB, Roehrborn CG, Schalken JA et al (2001) The progression of benign prostatic hyperplasia: examining the evidence and determining the risk. Eur Urol 39(4):390–399PubMedCrossRef Anderson JB, Roehrborn CG, Schalken JA et al (2001) The progression of benign prostatic hyperplasia: examining the evidence and determining the risk. Eur Urol 39(4):390–399PubMedCrossRef
3.
go back to reference Oelke M, Gravas S (2010) Relevance of benign prostatic hyperplasia and associated conditions for urologists, health care systems, and society. World J Urol 28(1):1–2PubMedCentralPubMedCrossRef Oelke M, Gravas S (2010) Relevance of benign prostatic hyperplasia and associated conditions for urologists, health care systems, and society. World J Urol 28(1):1–2PubMedCentralPubMedCrossRef
4.
go back to reference Rosen R, Altwein J, Boyle P et al (2003) Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 44(6):637–649PubMedCrossRef Rosen R, Altwein J, Boyle P et al (2003) Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 44(6):637–649PubMedCrossRef
5.
go back to reference Verhamme KM, Dieleman JP, Bleumink GS et al (2002) Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care—the Triumph project. Eur Urol 42(4):323–328PubMedCrossRef Verhamme KM, Dieleman JP, Bleumink GS et al (2002) Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care—the Triumph project. Eur Urol 42(4):323–328PubMedCrossRef
6.
go back to reference Sarma AV, Wei JT (2012) Benign prostatic hyperplasia and lower urinary tract symptoms. N Engl J Med 367(3):248–257PubMedCrossRef Sarma AV, Wei JT (2012) Benign prostatic hyperplasia and lower urinary tract symptoms. N Engl J Med 367(3):248–257PubMedCrossRef
7.
go back to reference Wei JT, Calhoun E, Jacobsen SJ (2005) Urologic diseases in America project: benign prostatic hyperplasia. J Urol 173:1256–1261PubMedCrossRef Wei JT, Calhoun E, Jacobsen SJ (2005) Urologic diseases in America project: benign prostatic hyperplasia. J Urol 173:1256–1261PubMedCrossRef
8.
go back to reference McConnell JD, Bruskewitz R, Walsh P et al (1998) The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride long-term efficacy and safety study group. N Engl J Med 338(9):557–563PubMedCrossRef McConnell JD, Bruskewitz R, Walsh P et al (1998) The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride long-term efficacy and safety study group. N Engl J Med 338(9):557–563PubMedCrossRef
9.
go back to reference Emberton M, Cornel EB, Bassi PF, Fourcade RO, Gómez JM, Castro R (2008) Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management. Int J Clin Pract 62(7):1076–1086PubMedCentralPubMedCrossRef Emberton M, Cornel EB, Bassi PF, Fourcade RO, Gómez JM, Castro R (2008) Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management. Int J Clin Pract 62(7):1076–1086PubMedCentralPubMedCrossRef
10.
go back to reference Oelke M, Bachmann A, Descazeaud A, et al. (2013) Guidelines on management of male lower urinary tract symptoms (LUTS), incl. Benign prostatic obstruction (BPO) Uroweb 2013. Last accessed 1 Aug 2013 Oelke M, Bachmann A, Descazeaud A, et al. (2013) Guidelines on management of male lower urinary tract symptoms (LUTS), incl. Benign prostatic obstruction (BPO) Uroweb 2013. Last accessed 1 Aug 2013
11.
go back to reference McVary KT, Roehrborn CG, Avins AL et al (2011) Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol 185:1793–1803PubMedCrossRef McVary KT, Roehrborn CG, Avins AL et al (2011) Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol 185:1793–1803PubMedCrossRef
12.
go back to reference McConnell JD, Roehrborn CG, Bautista OM et al (2003) Medical therapy of prostatic symptoms (MTOPS) research group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349(25):2387–2398PubMedCrossRef McConnell JD, Roehrborn CG, Bautista OM et al (2003) Medical therapy of prostatic symptoms (MTOPS) research group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349(25):2387–2398PubMedCrossRef
13.
go back to reference Füllhase C, Chapple C, Cornu JN et al (2013) Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms. Eur Urol 64(2):228–243PubMedCrossRef Füllhase C, Chapple C, Cornu JN et al (2013) Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms. Eur Urol 64(2):228–243PubMedCrossRef
14.
go back to reference Cornu JN, Cussenot O, Haab F, Lukacs B (2010) A widespread population study of actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia across Europe and beyond official clinical guidelines. Eur Urol 58(3):450–456PubMedCrossRef Cornu JN, Cussenot O, Haab F, Lukacs B (2010) A widespread population study of actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia across Europe and beyond official clinical guidelines. Eur Urol 58(3):450–456PubMedCrossRef
15.
go back to reference Nichol MB, Knight TK, Wu J et al (2009) Evaluating use patterns of and adherence to medications for benign prostatic hyperplasia. J Urol 181(5):2214–2221PubMedCrossRef Nichol MB, Knight TK, Wu J et al (2009) Evaluating use patterns of and adherence to medications for benign prostatic hyperplasia. J Urol 181(5):2214–2221PubMedCrossRef
16.
go back to reference Souverein PC, van Riemsdijk MM, de la Rosette JJ et al (2005) Treatment of benign prostatic hyperplasia and occurrence of prostatic surgery and acute urinary retention: a population-based cohort study in the Netherlands. Eur Urol 47(4):505–510PubMedCrossRef Souverein PC, van Riemsdijk MM, de la Rosette JJ et al (2005) Treatment of benign prostatic hyperplasia and occurrence of prostatic surgery and acute urinary retention: a population-based cohort study in the Netherlands. Eur Urol 47(4):505–510PubMedCrossRef
17.
go back to reference Logie J, Clifford GM, Farmer RD (2005) Incidence, prevalence and management of lower urinary tract symptoms in men in the UK. BJU Int 95(4):557–562PubMedCrossRef Logie J, Clifford GM, Farmer RD (2005) Incidence, prevalence and management of lower urinary tract symptoms in men in the UK. BJU Int 95(4):557–562PubMedCrossRef
18.
go back to reference Schneeweiss S, Avorn J (2005) A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 58(4):323–337PubMedCrossRef Schneeweiss S, Avorn J (2005) A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 58(4):323–337PubMedCrossRef
19.
go back to reference WHO Collaborating Centre for Drug Statistics Methodology (2003) ATC index with DDDs. WHO, Oslo WHO Collaborating Centre for Drug Statistics Methodology (2003) ATC index with DDDs. WHO, Oslo
21.
go back to reference Boyle P, Robertson C, Mazzetta C et al (2003) The prevalence of lower urinary tract symptoms in men and women in four centres. The UrEpik study. BJU Int 92(4):409–414PubMedCrossRef Boyle P, Robertson C, Mazzetta C et al (2003) The prevalence of lower urinary tract symptoms in men and women in four centres. The UrEpik study. BJU Int 92(4):409–414PubMedCrossRef
22.
go back to reference AUA practice guidelines committee. AUA guideline on management of benign prostatic hyperplasia (2003) Chapter 1: diagnosis and treatment recommendations. J Urol 170(2 Pt 1):530–547 AUA practice guidelines committee. AUA guideline on management of benign prostatic hyperplasia (2003) Chapter 1: diagnosis and treatment recommendations. J Urol 170(2 Pt 1):530–547
23.
go back to reference Strope SA, Elliott SP, Saigal CS, Smith A, Wilt TJ, Wei JT (2011) Urologic diseases in America project. Urologist compliance with AUA best practice guidelines for benign prostatic hyperplasia in Medicare population. Urology 78(1):3–9PubMedCentralPubMedCrossRef Strope SA, Elliott SP, Saigal CS, Smith A, Wilt TJ, Wei JT (2011) Urologic diseases in America project. Urologist compliance with AUA best practice guidelines for benign prostatic hyperplasia in Medicare population. Urology 78(1):3–9PubMedCentralPubMedCrossRef
24.
go back to reference Watson V, Ryan M, Brown CT et al (2004) Eliciting preferences for drug treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol 172(6 Pt 1):2321–2325PubMedCrossRef Watson V, Ryan M, Brown CT et al (2004) Eliciting preferences for drug treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol 172(6 Pt 1):2321–2325PubMedCrossRef
25.
go back to reference Boyle P, Roehrborn C, Harkaway R et al (2004) 5-alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery. Eur Urol 45(5):620–626PubMedCrossRef Boyle P, Roehrborn C, Harkaway R et al (2004) 5-alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery. Eur Urol 45(5):620–626PubMedCrossRef
26.
go back to reference Roehrborn CG, Siami P, Barkin J et al (2010) The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 57:123–131PubMedCrossRef Roehrborn CG, Siami P, Barkin J et al (2010) The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 57:123–131PubMedCrossRef
27.
go back to reference Robert G, Descazeaud A, de la Taille A (2011) Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: who are the high-risk patients and what are the best treatment options? Curr Opin Urol 21(1):42–48PubMedCrossRef Robert G, Descazeaud A, de la Taille A (2011) Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: who are the high-risk patients and what are the best treatment options? Curr Opin Urol 21(1):42–48PubMedCrossRef
28.
go back to reference Roehrborn C, Barkin J, Siami P et al (2011) Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind combination of avodart and tamsulosin (CombAT) trial. BJU Int 107(6):946–954PubMedCrossRef Roehrborn C, Barkin J, Siami P et al (2011) Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind combination of avodart and tamsulosin (CombAT) trial. BJU Int 107(6):946–954PubMedCrossRef
29.
go back to reference Souverein PC, Erkens JA, de la Rosette JJ et al (2003) Drug treatment of benign prostatic hyperplasia and hospital admission for BPH-related surgery. Eur Urol 43(5):528–534PubMedCrossRef Souverein PC, Erkens JA, de la Rosette JJ et al (2003) Drug treatment of benign prostatic hyperplasia and hospital admission for BPH-related surgery. Eur Urol 43(5):528–534PubMedCrossRef
30.
go back to reference Sarrazin MS, Rosenthal GE (2012) Finding pure and simple truths with administrative data. JAMA 307(13):1433–1435PubMedCrossRef Sarrazin MS, Rosenthal GE (2012) Finding pure and simple truths with administrative data. JAMA 307(13):1433–1435PubMedCrossRef
Metadata
Title
Actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia: temporal trends of prescription and hospitalization rates over 5 years in a large population of Italian men
Authors
Luca Cindolo
Luisella Pirozzi
Caterina Fanizza
Marilena Romero
Petros Sountoulides
Claus G. Roehrborn
Vincenzo Mirone
Luigi Schips
Publication date
01-04-2014
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 4/2014
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-013-0587-8

Other articles of this Issue 4/2014

International Urology and Nephrology 4/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.